American College of Clinical Pharmacy
      Search      Cart
         

2024 ACCP Annual Meeting Abstracts

Submission Deadlines

  • June 15, 2024: Submission deadline for all categories of abstracts EXCEPT Research-in-Progress (Research-in-Progress is for Students, Residents and Fellows only).
  • August 15, 2024: Submission deadline for Research-in-Progress (Students, Residents and Fellows only).
  • Invite Only Abstract Categories have unique submission deadlines, see each category below.

Acceptance Notification

  • August 15, 2024: Authors of all abstract categories, EXCEPT Research-in-Progress, will be notified of acceptance or declination no later than this date.
  • September 1, 2024: Authors of Research-in-Progress abstracts will be notified of acceptance or declination no later than this date.

 

All investigators in the field of clinical pharmacy and clinical pharmacology, ACCP members and nonmembers alike, are invited to submit abstracts to be considered for presentation at the 2024 ACCP Annual Meeting in Phoenix, Arizona. Important Note: Scoping Reviews is a new abstract category for the 2024 ACCP Annual Meeting. If interested in submitting a Scoping Review, please review the evaluation criteria prior to abstract submission.

All abstracts accepted and presented, except for "Encore" and "Research-in-Progress" presentations, will have full-text abstracts published online in JACCP, an official journal of ACCP. Only the abstract title, authors, and original citation will be published for "Encore" presentations.

 

Advances in International Clinical Pharmacy Practice, Education, or Training:  Abstract Submission Deadline: June 15, 2024, 11:59 p.m. (PST)

Word Count: All abstract categories (with the exception of Encore submissions) have a 300-count word limit.

Abstracts must describe the delivery of, justification or documentation for, and significance of clinical pharmacy practice, education, or training outside of the United States. Abstracts may be descriptive and need not contain an evaluative component.

  • Abstracts must be structured with the section headers of: Service or program, justification/documentation, adaptability, and significance.
  • Abstracts will be evaluated based on the originality of the service or program to the specific setting, adequacy of justification/documentation, adaptability to other settings, and significance to international clinical pharmacy advancement. For ACCP's specific criteria, click here.

Case Reports:  Abstract Submission Deadline: June 15, 2024, 11:59 p.m. (PST)

Word Count: All abstract categories (with the exception of Encore submissions) have a 300-count word limit.

Abstracts of case reports must update and expand therapeutic insights and possibilities or generate research hypotheses. While narrative in nature, these abstracts must stress the "evidence" for the authors' conclusions by describing the process followed to understand the findings and possible mechanisms involved in the patient's case, how the patient was evaluated and treated, and a specific description of the outcome.

  • Abstracts must be structured with the section headers:  Introduction, case, discussion, and conclusion.
  • Case report abstracts will be evaluated based on the abstract criteria recommended by the CARE Guidelines (CAse REport Group, http://www.care-statement.org/resources/checklist): uniqueness of report, clinical findings presented, outcomes documented, and "take-away" lessons. For ACCP's specific evaluation criteria, click here.
  • Abstracts of case reports presented elsewhere, but important to clinical pharmacy, are encouraged as "Encore" submissions (see Encore Presentation details below).

Clinical Pharmacy Forum:  Abstract Submission Deadline: June 15, 2024, 11:59 p.m. (PST)

Word Count: All abstract categories (with the exception of Encore submissions) have a 300-count word limit.

Abstracts must describe the delivery of, justification or documentation for, and impact/significance of innovative clinical pharmacy services previously implemented. Abstracts that address components of the ACCP Standards of Practice for Clinical Pharmacists (see www.accp.com/standards) and/or describe efforts to develop, advance, or position clinical pharmacists to optimize patient care are encouraged. Abstracts may be descriptive and need not contain an evaluative component.

  • Abstracts must be structured with the section headers of: Service or program, justification/documentation, adaptability, and significance.
  • Descriptions of planned services or programs will not be accepted.
  • Abstracts will be evaluated based on originality of the service or program, adequacy of justification/documentation, adaptability to other settings, and significance to clinical pharmacy. For ACCP's specific evaluation criteria, click here.
  • Abstracts presented elsewhere, but important to clinical pharmacy, are encouraged as "Encore" submissions (see Encore Presentation details below).

Encore Presentation:  Abstract Submission Deadline: June 15, 2024, 11:59 p.m. (PST))

Word Count: All abstract categories (with the exception of Encore submissions) have a 300-count word limit. Submission and evaluation criteria are those of the Original Research, Systematic Review/Meta-Analysis, or Case Reports, categories, except that the same abstract was presented elsewhere or published in abstract form only prior to this meeting.

  • Abstracts submitted for Encore Presentations must not be modified from the previously presented/published version. This includes the title, authors, and abstract body. The presenting author may change, but they must be an author on the original abstract.
  • The same abstract may not be presented at more than one national ACCP event.
  • The full abstract will be published in the Meeting App, only.
  • Only the abstract title, authors, and original citation will be published in JACCP.
  • Encore Presentations will not be eligible for the Best Poster Awards.
  • Submit Encore Presentation abstracts as under the Encore Abstracts section. Select Original Research, Review/Meta-Analysis, or Case Reports when prompted. Provide the original citation when prompted and include a copy of the original abstract in the Abstract Text section of the submission database.

Original Research: Abstract Submission Deadline: June 15, 2024, 11:59 p.m. (PST)

Word Count: All abstract categories (with the exception of Encore submissions) have a 300 count word limit.

Abstracts must summarize quantitative or qualitative findings from completed research. Basic, clinical, translational, dissemination/implementation, or educational research are examples of acceptable research. Topics should appeal to a clinical pharmacy audience and may include research in drug metabolism, education/pedagogy, health services, medication safety, patient/population outcomes, pharmacokinetics, pharmacodynamics, pharmacoeconomics, pharmacoepidemiology, pharmacogenomics, pharmacology, or pharmacotherapy. Abstracts reporting in vitro or animal research are welcome.

  • Abstracts must be structured with the section headers of: Introduction, research question or hypothesis, study design, methods, results, and conclusions.
  • Abstracts will be evaluated based on merits of the research question/hypothesis, study design, originality, methods, data analysis, results, and conclusions. For ACCP's specific evaluation criteria, click here.
  • Descriptions of planned research efforts or preliminary data will not be accepted.
  • To be eligible for Best Poster, Student Best Poster, or Resident/Fellow Best Poster the abstract must fit and be submitted in this category. For specific eligibility criteria, click here.
  • Original research findings presented (in abstract form) elsewhere, but important to clinical pharmacy, are encouraged as "Encore" submissions (see Encore Presentation details below).
  • A previously presented abstract may form the basis for a new abstract to be submitted for consideration in the Original Research category if the previous abstract:
  1. was a descriptive report of planned research only,
  2. described preliminary results only and complete results are now available,
  3. was presented at a student, resident, or fellow conference focused on gaining presentation experience and/or formative feedback,
  4. was presented at an ACCP Chapter or PRN event, or
  5. conclusions have been added/modified based on a new hypothesis and data analysis of the original results database.

Residents and Fellows Research-in-Progress:  Abstract Submission Deadline: August 15, 2024, 11:59 p.m. (PST)

Word Count: All abstract categories (with the exception of Encore submissions) have a 300-count word limit.

Submission guidelines are those of an Original Research abstract except that the research effort is ongoing at the time of abstract submission.

  • The presenting author must be in a post-graduate training program (PGY-1 or PGY-2 residency, Ph.D./Masters graduate degree program, or fellowship training program).
  • Abstracts submitted in the Research-in-Progress category are not eligible for the Resident and Fellow Best Poster competition. *Note: to be eligible for the Best Poster competition, the research must meet the criteria for and be submitted under the Original Research category, indicating that it was conducted by a resident or fellow.
  • All papers will be assigned to poster format.
  • Research-in-Progress abstracts will be published in the Meeting App, only. 

Student Research-in-Progress:  Abstract Submission Deadline: August 15, 2024, 11:59 p.m. (PST)

Word Count: All abstract categories (with the exception of Encore submissions) have a 300-count word limit.

Submission guidelines are those of an Original Research abstract except that the research effort is ongoing at the time of abstract submission.

  • The presenting author must be a first professional degree (Pharm.D. or B.S. Pharm.) student. Note: students in Ph.D./Master's degree programs are welcome in the Resident and Fellow Research-in-Progress category.
  • Abstracts submitted in the Research-in-Progress category are not eligible for the Student Best Poster competition. *Note: to be eligible for the Best Poster competitions, the research must meet the criteria for and be submitted under the Original Research category, indicating that it was conducted by a student.
  • All papers will be assigned to poster format.
  • Research-in-Progress abstracts will be published in the Meeting App, only.

Scoping Reviews/:Abstract Submission Deadline: June 15, 2024, 11:59 p.m. (PST)

Word Count: All abstract categories (with the exception of Encore submissions) have a 300-count word limit.

Abstracts must describe a scoping review adhering to the guidelines and definitions established by Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Scoping Reviews (PRISMA-ScR, click here Abstracts must describe a scoping review adhering to the guidelines established by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR). Submissions should highlight the objectives, findings, and implications of the review, emphasizing its contribution to knowledge and identifying gaps for further research. (Note: Scoping reviews are distinct from traditional literature reviews in their broader focus and exploratory nature.).

    • Abstracts presented elsewhere, but important to clinical pharmacy, are encouraged as "Encore" submissions.

Systematic Reviews/:Abstract Submission Deadline: June 15, 2024, 11:59 p.m. (PST)

Word Count: All abstract categories (with the exception of Encore submissions) have a 300-count word limit.

Abstracts must describe a systematic review adhering to the guidelines and definitions established by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA, http://www.prisma-statement.org/>http://www.prisma-statement.org/) and include the 12-items published in the PRISMA for Abstracts checklist (http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001419).

  • Abstracts must be structured with the PRISMA for Abstracts format: Background, methods, results, discussion, and other.
  • Abstracts will be evaluated based on merits of the 12 PRISMA for Abstracts checklist items: Title, objectives, eligibility criteria, information sources, risk of bias, included studies, synthesis of results, description of the effect, strengths and limitations of evidence, interpretation, funding, and registration. For ACCP's specific evaluation criteria, click here.
  • Abstracts presented elsewhere, but important to clinical pharmacy, are encouraged as "Encore" submissions (see Encore Presentation details below).

Invite Only Abstract Categories

PRN Contributed Papers:  Abstract Deadline: September 1, 2024, 11:59 p.m. (PST)

Word Count: 300 count word limit.

  • Abstracts may be descriptive and need not contain an evaluative component.
  • There are no required headers for this abstract category.
  • Abstracts will not be peer reviewed (and therefore not published in JACCP).

Mentored Research Investigator Training Program (MeRIT) ONLY, Proposed Research: MeRIT Proposed Research Abstract Deadline: September 1, 2024, 11:59 p.m. (PST)

Word Count: 300 count word limit.

    • Abstracts must be structured with the section headers of: Introduction, research question or hypothesis, study design, methods, results, and conclusions.

Mentored Research Investigator Training Program (MeRIT) ONLY, Completed Research: MeRIT Completed Research Abstract Deadline: September 1, 2024, 11:59 p.m. (PST)

Word Count: 300 count word limit.

  • Abstracts must be structured with the section headers of: Introduction, research question or hypothesis, study design, methods, results, and conclusions.

Acceptance Notification

  • August 15, 2024: Authors of all abstract categories, EXCEPT Research-in-Progress, will be notified of acceptance or declination no later than this date.
  • September 1, 2024: Authors of Research-in-Progress abstracts will be notified of acceptance or declination no later than this date.

ACCP Best Poster Competitions

Student Best Poster Competition

To be considered for this award:

  1. Research must have been conducted by the primary author while a first professional degree student (B.S. Pharm or Pharm.D.).
  2. The primary author must be the presenter of the poster.
  3. Abstract submission must occur within one year of the primary author's completion of first professional degree.
  4. Papers must represent completed research and be submitted under the Original Research category. Papers submitted in the Student Research in Progress category are not eligible for this competition.

Resident/Fellow Best Poster Competition

To be considered for this award:

  1. Research must have been conducted by the primary author while a post-Pharm.D. resident or fellow trainee.
  2. The primary author must be the presenter of the poster.
  3. Abstract submission must occur within one year of the primary author's completion of training program.
  4. Papers must represent completed research and be submitted under the Original Research category. Papers submitted in the Resident and Fellow Research in Progress category are not eligible for this competition.